Drugs / BIFIDOBACTERIUM SPP.
BIFIDOBACTERIUM SPP.
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07188909 | Sep 2025 → Mar 2026 overdue | acute graft versus host disease | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| — | NCT06287931 | Jan 2024 → Jun 2025 | gallstones | Shandong Linglong Yingcheng Hospital | Unknown | No outcome recorded |
| — | NCT06325605 | Mar → Oct 2022 | — | Zhen-Hong Hu | Completed | No outcome recorded |
| — | NCT03330184 | Oct 2015 → Apr 2018 | — | Xijing Hospital | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIFIDOBACTERIUM SPP. | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297912 ↗ |
| Known as | Bifidobacteria | “Bifidobacteria, 210 mg po tid x 6 months” NCT06287931 ↗ |
| Known as | Bifidobacterium | “Target isolation and culture of core beneficial bacteria (Lactobacillus and Bifidobacterium)” NCT07188909 ↗ |
| Known as | Bifidobacterium nos | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297912 ↗ |
| Modality | Other / unclassified | “Bifidobacterium, as a familiar probiotics” NCT03330184 ↗ |
| Route | Oral | “Bifidobacteria, 210 mg po tid x 6 months” NCT06287931 ↗ |